Physicians' Academy for Cardiovascular Education

siRNA therapy and LDL-C

Follow news on the evolving field of siRNA therapy and lowerting of LDL-c

Sustained LDL-c lowering with PCSK9 siRNA in patients with prior MI

News - Apr. 19, 2022

ACC 2022 A post hoc pooled analysis from the ORION-10 and ORION-11 trials showed that inclisiran, compared with placebo, in addition to statin and/or ezetimibe provided effective and sustained LDL-c lowering in patients with prior MI.

Beginning of an era: Treatment of elevated Lp(a)

3' education - Apr. 6, 2022 - Steven Nissen, MD
A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we going to be able to treat this disorder”, Nissen said.

ACC 2022 A phase 1 study showed that a siRNA targeting LPA mRNA reduced Lp(a) up to 98%. “It is an early study, this has got a long way to go, but we are optimistic that we are beginning an era where we are going to be able to treat this disorder”, Nissen said.

siRNA targeting LPA mRNA lowers Lp(a) levels

News - Apr. 3, 2022

ACC 2022 A phase 1 single ascending dose study showed that subcutaneous injection of SLN360, an siRNA targeting mRNA for the LPA gene, lowered Lp(a) up to 98% in adults with elevated Lp(a) levels.

FDA approval for PCSK9 siRNA to lower LDL-c

News - Dec. 23, 2021

The FDA has approved the small interfering RNA (siRNA) PCKS9 therapy inclisiran to lower LDL-c with two doses a year, after a first dose and one at 3 months, for treatment of adults with clinical ASCVD or FH.

E-learning Redefining intensive LDL-c management in high CV risk patients – The case for combination therapy

Accredited E-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

Real-world evidence shows that the majority of patients do not achieve their LDL-c target goals. Where do we fall short in the need for combination therapy?

Expanding therapeutic options for LDL-c lowering

10' education - Oct. 1, 2021 - Prof. Christie Ballantyne, MD - Online CME
The new therapeutic options for LDL-c lowering, bempedoic acid and inclisiran, are discussed by prof. Ballantyne. How do these drugs lower LDL-c and what are the findings in phase III programs?

The new therapeutic options for LDL-c lowering, bempedoic acid and inclisiran, are discussed by prof. Ballantyne. How do these drugs lower LDL-c and what are the findings in phase III programs?

NHS agreement on population health management approach using PCSK9 siRNA therapy

News - Sep. 7, 2021

The NHS has made an agreement on a population health management approach in those eligible for the PCSK9 siRNA inclisiran.

PCSK9 siRNA reduces LDL-c in patients with and without polyvascular disease

News - Sep. 6, 2021

ESC 2021 This pooled, post-hoc analysis of ORION-9, -10, and -11 showed that inclisiran significantly reduced LDL-c compared placebo in patients with and without polyvascular disease.

Safety of PCSK9 siRNA demonstrated in pooled data analysis

News - June 1, 2021

EAS 2021 A pooled data analysis of ORION-9, 10 and 11 showed no changes in hematological and immunological biomarkers in patients with ASCVD or risk equivalent treated with inclisiran over a treatment period of 540 days.

Pooled analysis of three trials with PCSK9 siRNA in patients with HeFH or ASCVD

Literature - Apr. 20, 2021 - Wright RS et al. - J Am Coll Cardiol. 2021

This pooled patient-level analysis of three phase 3 trials (ORION-9, -10 and -11) shows that inclisiran reduces LDL-c on average by 50.7% compared to placebo in patients on maximally tolerated statin-therapy.

The gap between guideline LDL-c goals and current practice: How are we doing?

15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME
In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?

Experts in dialogue In this video, prof. Mach and prof. Stroes answer the question: How are we performing in Europe with regard to LDL-c goal attainment in very high risk patients?

PCSK9i siRNA therapy for lowering LDL-c levels approved by EC

News - Dec. 14, 2020

Inclisiran has received approval from the European Commission (EC) for the treatment of adult patients with atherosclerotic CVD (ASCVD), ASCVD-risk equivalent and heterozygous FH.